| |
Public Act 095-0239
Public Act 0239 95TH GENERAL ASSEMBLY
|
Public Act 095-0239 |
HB0457 Enrolled |
LRB095 04451 RLC 26428 b |
|
| AN ACT concerning criminal law.
| Be it enacted by the People of the State of Illinois,
| represented in the General Assembly:
| Section 5. The Illinois Controlled Substances Act is | amended by changing Section 204 as follows:
| (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
| Sec. 204. (a) The controlled substances listed in this | Section are
included in Schedule I.
| (b) Unless specifically excepted or unless listed in | another
schedule, any of the following opiates, including their | isomers,
esters, ethers, salts, and salts of isomers, esters, | and ethers,
whenever the existence of such isomers, esters, | ethers and salts is
possible within the specific chemical | designation:
| (1) Acetylmethadol;
| (1.1) Acetyl-alpha-methylfentanyl
| (N-[1-(1-methyl-2-phenethyl)-
| 4-piperidinyl]-N-phenylacetamide);
| (2) Allylprodine;
| (3) Alphacetylmethadol, except
| levo-alphacetylmethadol (also known as levo-alpha-
| acetylmethadol, levomethadyl acetate, or LAAM);
| (4) Alphameprodine;
|
| (5) Alphamethadol;
| (6) Alpha-methylfentanyl
| (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
| propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
| propanilido) piperidine;
| (6.1) Alpha-methylthiofentanyl
| (N-[1-methyl-2-(2-thienyl)ethyl-
| 4-piperidinyl]-N-phenylpropanamide);
| (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
| (7) 1-methyl-4-phenyl-4-proprionoxypiperidine (MPPP);
| (7.1) PEPAP
| (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
| (8) Benzethidine;
| (9) Betacetylmethadol;
| (9.1) Beta-hydroxyfentanyl
| (N-[1-(2-hydroxy-2-phenethyl)-
| 4-piperidinyl]-N-phenylpropanamide);
| (10) Betameprodine;
| (11) Betamethadol;
| (12) Betaprodine;
| (13) Clonitazene;
| (14) Dextromoramide;
| (15) Diampromide;
| (16) Diethylthiambutene;
| (17) Difenoxin;
| (18) Dimenoxadol;
|
| (19) Dimepheptanol;
| (20) Dimethylthiambutene;
| (21) Dioxaphetylbutyrate;
| (22) Dipipanone;
| (23) Ethylmethylthiambutene;
| (24) Etonitazene;
| (25) Etoxeridine;
| (26) Furethidine;
| (27) Hydroxpethidine;
| (28) Ketobemidone;
| (29) Levomoramide;
| (30) Levophenacylmorphan;
| (31) 3-Methylfentanyl
| (N-[3-methyl-1-(2-phenylethyl)-
| 4-piperidyl]-N-phenylpropanamide);
| (31.1) 3-Methylthiofentanyl
| (N-[(3-methyl-1-(2-thienyl)ethyl-
| 4-piperidinyl]-N-phenylpropanamide);
| (32) Morpheridine;
| (33) Noracymethadol;
| (34) Norlevorphanol;
| (35) Normethadone;
| (36) Norpipanone;
| (36.1) Para-fluorofentanyl
| (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
| 4-piperidinyl]propanamide);
|
| (37) Phenadoxone;
| (38) Phenampromide;
| (39) Phenomorphan;
| (40) Phenoperidine;
| (41) Piritramide;
| (42) Proheptazine;
| (43) Properidine;
| (44) Propiram;
| (45) Racemoramide;
| (45.1) Thiofentanyl
| (N-phenyl-N-[1-(2-thienyl)ethyl-
| 4-piperidinyl]-propanamide);
| (46) Tilidine;
| (47) Trimeperidine;
| (48) Beta-hydroxy-3-methylfentanyl (other name:
| N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
| N-phenylpropanamide).
| (c) Unless specifically excepted or unless listed in | another
schedule, any of the following opium derivatives, its | salts, isomers
and salts of isomers, whenever the existence of | such salts, isomers and
salts of isomers is possible within the | specific chemical designation:
| (1) Acetorphine;
| (2) Acetyldihydrocodeine;
| (3) Benzylmorphine;
| (4) Codeine methylbromide;
|
| (5) Codeine-N-Oxide;
| (6) Cyprenorphine;
| (7) Desomorphine;
| (8) Diacetyldihydromorphine (Dihydroheroin);
| (9) Dihydromorphine;
| (10) Drotebanol;
| (11) Etorphine (except hydrochloride salt);
| (12) Heroin;
| (13) Hydromorphinol;
| (14) Methyldesorphine;
| (15) Methyldihydromorphine;
| (16) Morphine methylbromide;
| (17) Morphine methylsulfonate;
| (18) Morphine-N-Oxide;
| (19) Myrophine;
| (20) Nicocodeine;
| (21) Nicomorphine;
| (22) Normorphine;
| (23) Pholcodine;
| (24) Thebacon.
| (d) Unless specifically excepted or unless listed in | another
schedule, any material, compound, mixture, or | preparation which contains
any quantity of the following | hallucinogenic substances, or which
contains any of its salts, | isomers and salts of isomers, whenever the
existence of such | salts, isomers, and salts of isomers is possible
within the |
| specific chemical designation (for the purposes of this
| paragraph only, the term "isomer" includes the optical, | position and
geometric isomers):
| (1) 3,4-methylenedioxyamphetamine
| (alpha-methyl,3,4-methylenedioxyphenethylamine,
| methylenedioxyamphetamine, MDA);
| (1.1) Alpha-ethyltryptamine
| (some trade or other names: etryptamine;
| MONASE; alpha-ethyl-1H-indole-3-ethanamine;
| 3-(2-aminobutyl)indole; a-ET; and AET);
| (2) 3,4-methylenedioxymethamphetamine (MDMA);
| (2.1) 3,4-methylenedioxy-N-ethylamphetamine
| (also known as: N-ethyl-alpha-methyl-
| 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
| and MDEA);
| (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
| (4) 3,4,5-trimethoxyamphetamine (TMA);
| (5) (Blank);
| (6) Diethyltryptamine (DET);
| (7) Dimethyltryptamine (DMT);
| (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
| (9) Ibogaine (some trade and other names:
| 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
| 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
| indole; Tabernanthe iboga);
| (10) Lysergic acid diethylamide;
|
| (10.5) Salvia divinorum (meaning all parts of the plant | presently classified
botanically as Salvia divinorum, | whether growing or not, the
seeds thereof, any extract from | any part of that plant, and every compound,
manufacture, | salts, isomers, and salts of
isomers whenever the existence | of such salts, isomers, and salts of
isomers is possible | within the specific chemical designation, derivative, | mixture, or preparation of that plant, its
seeds or | extracts);
| (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
| (12) Peyote (meaning all parts of the plant presently | classified
botanically as Lophophora williamsii
williemaii
| Lemaire, whether growing or not, the
seeds thereof, any | extract from any part of that plant, and every compound,
| manufacture, salts, derivative, mixture, or preparation of | that plant, its
seeds or extracts);
| (13) N-ethyl-3-piperidyl benzilate (JB 318);
| (14) N-methyl-3-piperidyl benzilate;
| (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
| (also known as N-hydroxy-alpha-methyl-
| 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
| (15) Parahexyl; some trade or other names:
| 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
| dibenzo (b,d) pyran; Synhexyl;
| (16) Psilocybin;
| (17) Psilocyn;
|
| (18) Alpha-methyltryptamine (AMT);
| (19) 2,5-dimethoxyamphetamine
| (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
| (20) 4-bromo-2,5-dimethoxyamphetamine
| (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
| 4-bromo-2,5-DMA);
| (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
| Some trade or other names: 2-(4-bromo-
| 2,5-dimethoxyphenyl)-1-aminoethane;
| alpha-desmethyl DOB, 2CB, Nexus;
| (21) 4-methoxyamphetamine
| (4-methoxy-alpha-methylphenethylamine;
| paramethoxyamphetamine; PMA);
| (22) (Blank);
| (23) Ethylamine analog of phencyclidine.
| Some trade or other names:
| N-ethyl-1-phenylcyclohexylamine,
| (1-phenylcyclohexyl) ethylamine,
| N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
| (24) Pyrrolidine analog of phencyclidine. Some trade | or other names:
1-(1-phenylcyclohexyl) pyrrolidine, PCPy, | PHP;
| (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
| (26) 2,5-dimethoxy-4-ethylamphetamine
| (another name: DOET);
| (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
|
| (another name: TCPy);
| (28) (Blank);
| (29) Thiophene analog of phencyclidine (some trade
| or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
| 2-thienyl analog of phencyclidine; TPCP; TCP);
| (30) Bufotenine (some trade or other names:
| 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
| 3-(2-dimethylaminoethyl)-5-indolol;
| 5-hydroxy-N,N-dimethyltryptamine;
| N,N-dimethylserotonin; mappine).
| (e) Unless specifically excepted or unless listed in | another
schedule, any material, compound, mixture, or | preparation which contains
any quantity of the following | substances having a depressant effect on
the central nervous | system, including its salts, isomers, and salts of
isomers | whenever the existence of such salts, isomers, and salts of
| isomers is possible within the specific chemical designation:
| (1) mecloqualone;
| (2) methaqualone; and
| (3) gamma hydroxybutyric acid.
| (f) Unless specifically excepted or unless listed in | another schedule,
any material, compound, mixture, or | preparation which contains any quantity
of the following | substances having a stimulant effect on the central nervous
| system, including its salts, isomers, and salts of isomers:
| (1) Fenethylline;
|
| (2) N-ethylamphetamine;
| (3) Aminorex (some other names:
| 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
| 4-5-dihydro-5-phenyl-2-oxazolamine) and its
| salts, optical isomers, and salts of optical isomers;
| (4) Methcathinone (some other names:
| 2-methylamino-1-phenylpropan-1-one;
| Ephedrone; 2-(methylamino)-propiophenone;
| alpha-(methylamino)propiophenone; N-methylcathinone;
| methycathinone; Monomethylpropion; UR 1431) and its
| salts, optical isomers, and salts of optical isomers;
| (5) Cathinone (some trade or other names:
| 2-aminopropiophenone; alpha-aminopropiophenone;
| 2-amino-1-phenyl-propanone; norephedrone);
| (6) N,N-dimethylamphetamine (also known as:
| N,N-alpha-trimethyl-benzeneethanamine;
| N,N-alpha-trimethylphenethylamine);
| (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
| 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine).
| (g) Temporary listing of substances subject to emergency | scheduling.
Any material, compound, mixture, or preparation | that contains any quantity
of the following substances:
| (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
| (benzylfentanyl), its optical isomers, isomers, salts,
| and salts of isomers;
| (2) N-[1(2-thienyl)
|
| methyl-4-piperidyl]-N-phenylpropanamide (thenylfentanyl),
| its optical isomers, salts, and salts of isomers.
| (Source: P.A. 90-382, eff. 8-15-97; 91-714, eff. 6-2-00; | revised 10-18-05.)
|
Effective Date: 1/1/2008
|
|
|